Precision Medicine and Companion Diagnostics

In a recent Medical Device Network interview, Russell Bradley, President and General Manager of CNSide Diagnostics, emphasized the essential role of companion diagnostics (CDx) in advancing targeted cancer therapies.

As oncology treatment becomes increasingly personalized, companion diagnostics enable clinicians to identify the right therapy for the right patient at the right time, helping to maximize effectiveness and improve outcomes.

CNSide Diagnostics’ Contribution

CNSide Diagnostics is at the forefront of precision diagnostics for CNS cancers, including leptomeningeal metastases (LM). The CNSide CSF assay platform provides:

• Sensitive detection of CNS tumor cells
• Longitudinal monitoring of disease progression
• Actionable insights to inform personalized treatment strategies

Learn more about our work: CNSide Diagnostics

Why It Matters

• Companion diagnostics help tailor therapies to individual patient profiles.
• Tools like CNSide’s CSF assay are critical in neuro-oncology, where early detection and monitoring significantly impact treatment decisions.
• Integration of diagnostics and targeted therapy supports the broader movement toward precision medicine and better patient outcomes.

#CNSide #CompanionDiagnostics #PrecisionMedicine #CancerDiagnostics #TargetedTherapies #NeuroOncology #LeptomeningealMetastases #BrainCancer #OncologyInnovation #ClinicalResearch